Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Multiple myeloma cells’ capacity to decompose H 2 O 2 determines lenalidomide sensitivity

Sinto Sebastian, Yuan X. Zhu, Esteban Braggio, Chang-Xin Shi, Sonali C. Panchabhai, Scott A. Van Wier, Greg J. Ahmann, Marta Chesi, P. Leif Bergsagel, A. Keith Stewart, Rafael Fonseca

Blood (2017) 129 (8): 991–1007.

https://doi.org/10.1182/blood-2016-09-738872

Published: 2017

Includes: Supplemental data

Journal Articles

Immunomodulatory Drugs Inhibit H 2 O 2 Decomposition in Multiple Myeloma Cells and Its Mediated Cytotoxicity Is Determined By Cellular Antioxidative Capacity

Sinto Sebastian Chirackal, PhD, Yuan Xiao Zhu, PhD, Esteban Braggio, PhD, Chang-Xin Shi, PhD, Sonali Panchabhai, MBBS, Gregory Ahmann, BS, Scott A. Van Wier, BS, Marta Chesi, PhD, Leif Bergsagel, MD PhD, Keith Stewart, MD, Rafael Fonseca, MD

Blood (2015) 126 (23): 2475.

https://doi.org/10.1182/blood.V126.23.2475.2475

Published: 2015

Journal Articles

Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach

Angela Baker, Esteban Braggio, Susanna Jacobus, Sungwon Jung, Dirk Larson, Terry Therneau, Angela Dispenzieri, Scott A. Van Wier, Gregory Ahmann, Joan Levy, Louise Perkins, Seungchan Kim, Kimberly Henderson, David Vesole, S. Vincent Rajkumar, Diane F. Jelinek, John Carpten, Rafael Fonseca

Blood (2013) 121 (16): 3147–3152.

https://doi.org/10.1182/blood-2012-07-443606

Published: 2013

Includes: Supplemental data

Journal Articles

Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone

Shaji K. Kumar, Hajime Uno, Susanna J. Jacobus, Scott A. Van Wier, Greg J. Ahmann, Kimberly J. Henderson, Natalie S. Callander, Jessica L. Haug, David S. Siegel, Philip R. Greipp, Rafael Fonseca, S. Vincent Rajkumar

Blood (2011) 118 (16): 4359–4362.

https://doi.org/10.1182/blood-2011-03-342089

Published: 2011

Journal Articles

The t(4;14) Is Present in Patients with Early Stage Plasma Cell Proliferative Disorders Including MGUS and Smoldering Multiple Myeloma (SMM).

Scott A. Van Wier, BS, Gregory J. Ahmann, BS, Kimberly J. Henderson, Philip R. Greipp, MD, S. Vincent Rajkumar, MD, Dirk M. Larson, Angela Dispenzieri, MD, Morie A. Gertz, MD, Robert A. Kyle, MD, Rafael Fonseca, MD

Blood (2005) 106 (11): 1545.

https://doi.org/10.1182/blood.V106.11.1545.1545

Published: 2005

Journal Articles

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Philip R. Greipp, Mark R. Litzow, Kimberly J. Henderson, Scott A. Van Wier, Greg J. Ahmann, Rafael Fonseca

Blood (2005) 106 (8): 2837–2840.

https://doi.org/10.1182/blood-2005-04-1411

Published: 2005

Journal Articles

A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS

Wee Joo Chng, Scott A. Van Wier, Gregory J. Ahmann, Jerry M. Winkler, Syed M. Jalal, Peter Leif Bergsagel, Marta Chesi, Mike C. Trendle, Martin M. Oken, Emily Blood, Kim Henderson, Rafael Santana-Dávila, Robert A. Kyle, Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Philip R. Greipp, Rafael Fonseca

Blood (2005) 106 (6): 2156–2161.

https://doi.org/10.1182/blood-2005-02-0761

Published: 2005

Journal Articles

A Comprehensive Study of Chromosome 13 Abnormalities (Δ 13) in Multiple Myeloma Using High-Throughput, Array-Based Methods.

Angela S. Baker, Ph.D., Tammy Price-Troska, Michael L. Bittner, Ph.D., Scott A. Van Wier, Rachel Rempel, Gregory J. Ahmann, Tyler S. Pidgeon, Spyro Mousses, Ph.D., Bernie Futscher, Ph.D., Rafael D. Fonseca, M.D., John D. Carpten, Ph.D.

Blood (2004) 104 (11): 1417.

https://doi.org/10.1182/blood.V104.11.1417.1417

Published: 2004

Journal Articles

Clinical Implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32) and -17p13 (p53) Deletions in Myeloma Patients Treated with High Dose Therapy.

Morie Abraham Gertz, MD, Martha Q. Lacy, MD, Angela Dispenzieri, MD, Philip R. Greipp, MD, Mark R. Litzow, MD, Kim J. Henderson, BA, Scott A. Van Wier, BA, Gregory J. Ahmann, BA, Rafael Fonseca, MD

Blood (2004) 104 (11): 334.

https://doi.org/10.1182/blood.V104.11.334.334

Published: 2004

Journal Articles

Characterization of Waldenström Macroglobulinemia Subtypes using Global Gene Expression Profiling.

Tae-Hoon Chung, PhD, Seungchan Kim, PhD, Angela S. Baker, PhD, Tammy Price-Troska, BA, Ruifang Xu, PhD, Irene Ghobrial, MD, Philip R. Greipp, MD, S. Vincent Rajkumar, MD, Morie A. Gertz, MD, Scott A. Van Wier, BA, Gregory J. Ahmann, BA, John Carpten, PhD, Rafael Fonseca, MD

Blood (2004) 104 (11): 786.

https://doi.org/10.1182/blood.V104.11.786.786

Published: 2004

Journal Articles

Clinical and biologic implications of recurrent genomic aberrations in myeloma

Rafael Fonseca, Emily Blood, Montserrat Rue, David Harrington, Martin M. Oken, Robert A. Kyle, Gordon W. Dewald, Brian Van Ness, Scott A. Van Wier, Kimberly J. Henderson, Richard J. Bailey, Philip R. Greipp

Blood (2003) 101 (11): 4569–4575.

https://doi.org/10.1182/blood-2002-10-3017

Published: 2003

Journal Articles

Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions

Roelandt F. J. Schop, W. Michael Kuehl, Scott A. Van Wier, Gregory J. Ahmann, Tammy Price-Troska, Richard J. Bailey, Syed M. Jalal, Ying Qi, Robert A. Kyle, Philip R. Greipp, Rafael Fonseca

Blood (2002) 100 (8): 2996–3001.

https://doi.org/10.1182/blood.V100.8.2996

Published: 2002

Journal Articles

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients

Rafael Fonseca, Emily A. Blood, Martin M. Oken, Robert A. Kyle, Gordon W. Dewald, Richard J. Bailey, Scott A. Van Wier, Kimberly J. Henderson, James D. Hoyer, David Harrington, Neil E. Kay, Brian Van Ness, Philip R. Greipp

Blood (2002) 99 (10): 3735–3741.

https://doi.org/10.1182/blood.V99.10.3735

Published: 2002

NARROW

Multiple myeloma cells’ capacity to decompose H 2 O 2 determines lenalidomide sensitivity

Immunomodulatory Drugs Inhibit H 2 O 2 Decomposition in Multiple Myeloma Cells and Its Mediated Cytotoxicity Is Determined By Cellular Antioxidative Capacity

Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach

Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone

The t(4;14) Is Present in Patients with Early Stage Plasma Cell Proliferative Disorders Including MGUS and Smoldering Multiple Myeloma (SMM).

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS

A Comprehensive Study of Chromosome 13 Abnormalities (Δ 13) in Multiple Myeloma Using High-Throughput, Array-Based Methods.

Clinical Implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32) and -17p13 (p53) Deletions in Myeloma Patients Treated with High Dose Therapy.

Characterization of Waldenström Macroglobulinemia Subtypes using Global Gene Expression Profiling.

Clinical and biologic implications of recurrent genomic aberrations in myeloma

Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only